Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by New York University.
Recruitment status was  Recruiting
Information provided by:
New York University Identifier:
First received: August 11, 2009
Last updated: August 12, 2009
Last verified: August 2009
Tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) have been reported to reduce blood loss in the cardiac surgery literature but they have not been reported in use head-to-head in the orthopedic surgery literature. In a randomized, double-blind, prospective study we believe that TXA will be more effective than both EACA and placebo at reducing blood loss for corrective spinal surgery.

Condition Intervention Phase
Drug: Tranexamic Acid
Drug: Normal Saline
Drug: Epsilon aminocaproic acid
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Double-blinded Single-site Control Study Comparing Blood Loss Prevention of Tranexamic Acid (TXA) to Epsilon Aminocaproic Acid (EACA) for Corrective Spinal Surgery

Resource links provided by NLM:

Further study details as provided by New York University:

Primary Outcome Measures:
  • Total Blood Loss over Course of Stay (Intraoperative and Postoperatively until discharge) [ Time Frame: 1 Week ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Total Units of Autologous and allogenic transfusion (Both intraoperatively and postoperatively until discharge) [ Time Frame: 1 week ] [ Designated as safety issue: No ]
  • Length of Hospital Stay from admission until Patient Discharge [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Estimated Enrollment: 390
Study Start Date: December 2008
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Normal Saline
Patients infused with normal saline before and during the surgical procedure as a placebo.
Drug: Normal Saline
Experimental: Tranexamic acid
Patients receive TXA before and during the surgical case.
Drug: Tranexamic Acid
For TXA, the loading dose is 10mg/kg infused over 15 minutes, while the maintenance dose is 1/mg/kg hr.
Other Name: TXA
Experimental: Epsilon Aminocaproic Acid
Patients will receive EACA before and during the surgical case.
Drug: Epsilon aminocaproic acid
For EACA, the loading dose is 100mg/kg infused over 15 minutes, while the maintenance dose is 10mg/kg hr.
Other Name: Amicar, EACA

  Hide Detailed Description

Detailed Description:

Study Design The study is designed as a prospective, randomized, double-blinded control trial. The patient, researcher, surgeon, and anesthesiologist will all be blinded to the patient's treatment. Patients will either receive TXA, EACA, or normal saline. The study will determine and compare differences in blood loss intra-operatively and estimate blood loss postoperatively through monitoring of subfascial Hemovac drain outputs at the incision site between the three groups. Postoperatively, laboratory values, drain outputs, and clinical outcomes will be carefully followed.

The primary goal of this study is to compare the efficacy of TXA to EACA to placebo in patients undergoing corrective spinal surgery for adolescent idiopathic scoliosis (AIS), neuromuscular scoliosis (NMS), and with adult deformity (AD). Outcome measures will include intra-operative and perioperative blood loss, transfusion rates, complete blood counts, and coagulation profiles, as well as postoperative wound drainage, complications, and length of stay.

Standardized treatment protocol For EACA, the loading dose is 100mg/kg infused over 15 minutes, while the maintenance dose is 10mg/kg hr. For TXA, the loading dose is 10mg/kg infused over 15 minutes, while the maintenance dose is 1/mg/kg hr. Since TXA is prepared by pharmacy at a concentration ten times less than the concentration of EACA, the volume of medication administered during the loading and maintenance phase is identical. This is the ideal method for physician blinding and has been discussed in depth with the anesthesia department. The dosing regimen is also in accordance with existing guidelines and current literature. The literature also reports safely using TXA at a 100mg/kg loading dose followed by a 10mg/kg hr maintenance dose. However, improved efficacy at this higher dose of TXA has not been proven in a single orthopedic study. Since TXA is reported to be ten times more potent than EACA, delivering a dose of TXA that is ten times smaller than EACA is valid and well supported in the literature.

Surgical correction of the spine Dorsal lumbar access is achieved by a posterior lumbar skin incision along the midline. Paravertebral muscles are dissected away from bony structures taking care to achieve adequate hemostasis. Multi-level spinal osteotomies and/or releases of bony and ligamentous structures are performed to increase mobility of the spinal column. Bone grafts consisting of autologous bone or allograft are filled in to allow for bony fusion of the spinal column and limit motion. Pedicle screws are placed segmentally into vertebral bodies to provide adequate fixation of rod instrumentation. Stainless steel, titanium, or cobalt rods are placed to help correct and stabilize the spine while fusion occurs. Generally the greatest blood loss occurs during dissection and placement of pedicle screws while rod placement is associated with less blood loss. Subfascial Hemovac or Jackson-Pratt drains are placed at the wound site during closure to allow for adequate drainage and determination of post-operative blood loss.

Investigation schedule and follow-up Data will be collected pre-operatively regarding individual patient demographics, laboratory values, and the surgical procedure to be performed. Intra-operatively, data will be gathered to estimate blood loss and account for changes in fluid balance. Anesthesiologists are asked to maintain a MAP of 60 during the surgical exposure and anchor placement and a MAP of 70-90 during the surgical correction. Similarly, surgeons are asked to place only subfascial Hemovac drains at the incision site. These are both standard practice and have . Postoperatively, laboratory values, drain output, and clinical outcomes are carefully followed until the patient is discharged. Given the increased risk of renal failure with the use of Aprotinin changes in BUN to CR ratio are carefully monitored post-operatively. This data is recorded onto a de-identified data collection sheet by the researchers. These patient data sheets are then entered onto a protected electronic database, while the data sheets are stored as a back-up until the study is complete. Once the completed database is analyzed and summarized, the results will be presented to the involved participants without any identifiable patient information.

Statistical considerations While useful, this analysis is limited by the great variability in study design and control groups between prior orthopedic studies. Since no orthopedic study has compared TXA and EACA together, conducting a power analysis required pooling of data from two or three studies. This proved difficult, as control groups were dissimilar between the studies.

Power analysis was performed multiple times using data from several studies. When estimating the sample size required comparing TXA and EACA, attempts were made to choose two studies with similar intra-operative blood losses within the control groups. A cardiac study, albeit with dissimilar sample variance, was also used to estimate the sample size needed for this study. Finally, determining the sample size for outcomes of total blood loss and transfusion requirements proved difficult as even fewer studies reported these outcomes. Blood loss will be estimated in the operation room, but will also be calculated taking into account patient body mass, pre/postoperative hematocrit, and relative fluid balance. This will minimize the variance in reported blood loss. A power analysis will be performed again once 60 patients with AIS, NMS, or AD have been enrolled into the study.

With a single institution of surgeons and anesthesiologists participating in the study, we expect a smaller variation in operative blood loss than reported in prior studies. Data will not only be analyzed for all patients collectively, but will also be stratified by diagnosis (AIS, NMS, and AD). The purpose of stratifying into these groups is threefold. First, separation by diagnosis allows for more diligent control of patient-related factors that may affect blood loss and transfusion rate. Secondarily, stratification by diagnosis allows for a better understanding of which patients benefit most from one treatment option over another. Lastly, it allows for a broader application of the results from this study not only to patients with AIS, but to all spinal deformity patients.

An analysis of variance, univariate, and multivariate logistic regression analysis will be used to analyze the difference in outcomes. Odds ratios will be calculated regarding the risk for autologous or allogenic transfusion both intra and postoperatively. P-values will be calculated regarding the relative blood loss in the intra and postoperative periods as well. The groups will be analyzed to characterize the homogeneity of their pre-operative characteristics that may influence blood loss. Patients with AIS, NMS or AD will be stratified by primary diagnosis and analyzed separately but also collectively accounting for patient and surgery-related confounders. Non-continuous data will be analyzed with a non-parametric test. Pre-operative curve characteristics including Cobb angle and number of vertebrae fused will be categorized to ensure similar groups for comparison.


Ages Eligible for Study:   10 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Undergoing thoracic and/or lumbar surgery for correction of adolescent idiopathic scoliosis, neuromuscular scoliosis, or adult deformity for correction of condition via posterior spinal fusion of 6 levels or greater.

Exclusion Criteria:

  • No renal dysfunction identified by elevated blood urea nitrogen (BUN) and creatinine (CR) or BUN to CR ratio greater than 20:1
  • Hold religious and/or other beliefs limiting blood transfusion
  • Currently use anti-coagulant medication or have past medical history leading to abnormal coagulation profile pre-operatively
  • Significant past medical history preventing the use of TXA or EACA described in the protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00958581

Contact: Thomas J Errico, MD (212)263-7182
Contact: Kushagra Verma, MS (240)678-3725

United States, New York
New York University School of Medicine - Department of Orthopaedic Surgery - Spine Recruiting
New York, New York, United States, 10016
Principal Investigator: Thomas J Errico, MD         
Principal Investigator: Baron S Lonner, MD         
Sub-Investigator: Kushagra Verma, MS         
Sponsors and Collaborators
New York University
Principal Investigator: Thomas J Errico, MD New York University School of Medicine - Department of Orthopaedic Surgery
Principal Investigator: Baron S Lonner, MD New York University - Department of Orthopaedic Surgery
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: New York University School of Medicine - Department of Orthopaedic Surgery Identifier: NCT00958581     History of Changes
Other Study ID Numbers: TXA, Amicar, Placebo 
Study First Received: August 11, 2009
Last Updated: August 12, 2009
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Aminocaproic Acid
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2016